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Abstract
Aims/hypothesis Sucrose, non-fermenting 1/AMP-activated
protein kinase-related kinase (SNARK) is involved in
cellular stress responses linked to obesity and type 2
diabetes. We determined the role of SNARK in response
to metabolic stress and insulin action on glucose and lipid
metabolism in skeletal muscle.
Methods Vastus lateralis skeletal muscle biopsies were
obtained from normal glucose tolerant (n=35) and type 2
diabetic (n=31) men and women for SNARK expression
studies. Primary myotube cultures were derived from
biopsies obtained from normal glucose tolerant individuals
for metabolic studies.
Results SNARK (also known as NUAK2) mRNA expression
was unaltered between normal glucose tolerant individuals
and type 2 diabetic patients. SNARK expression was
increased in skeletal muscle from obese (BMI >31 kg/m
2)
normal glucose tolerant individuals and type 2 diabetic
patients (1.4- and 1.4-fold, respectively, p<0.05) vs
overweight (BMI <28 kg/m
2) normal glucose tolerant
individuals and type 2 diabetic patients. SNARK mRNA
was increased in myotubes exposed to palmitate (12-fold;
p<0.01), or TNF-α (25-fold, p<0.05), but not to oleate,
glucose or IL-6, whereas expression of the AMP-activated
protein kinase α2 subunit was unaltered. Small interfering
(si)RNA against SNARK reduced mRNA and protein in
myotubes by 61% and 60%, respectively (p<0.05).
SNARK siRNA was without effect on basal or insulin-
stimulated glucose uptake or lipid oxidation, and insuffi-
cient to rescue TNF-α- or palmitate-induced insulin
resistance.
Conclusions/interpretation Skeletal muscle SNARK expres-
sion is increased in human obesity, and in response to
metabolic stressors, but not type 2 diabetes. Partial SNARK
depletion failed to modify either glucose or lipid metabo-
lism, or protect against TNF-α- or palmitate-induced
insulin resistance in primary human myotubes.
Keywords AMPKactivation.Glucosemetabolism.Insulin
resistance.Lipidmetabolism.Obesity.Palmitate.Signal
transduction.siRNA.TNF-α.Type2diabetes
Abbreviations
AICAR 5-Aminoimidazole-4-carboxamide-1β-4-ribo-
furanoside
AMPK AMP-activated protein kinase
IR Insulin resistance
siRNA Small interfering RNA
SNARK Sucrose, non-fermenting 1/AMP-activated
protein kinase-related kinase
Introduction
The ability to adjust energy use and storage in times of fuel
surplus or deficiency is vital for survival throughout
evolution. AMP-activated protein kinase (AMPK) is known
as a master regulator of glucose and lipid metabolism in
mammals through sensing of the ratio of AMP:ATP in the
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DOI 10.1007/s00125-009-1465-xcell [1, 2]. Upon activation of AMPK, anabolic energy-
demanding pathways are switched off and catabolic ATP-
producing pathways are activated, thereby controlling
peripheral glucose and lipid homeostasis. Recently, a family
of AMPK-related kinases has been described, thereby
broadening the regulation of metabolism in response to
cellular stress to include novel protein kinases [3].
AMPKisa heterotrimericcomplexconsistingofacatalytic
AMP-sensitive α subunit and regulatory β and γ subunits.
Twelve protein kinases (BRSK1, BRSK2, NUAK1, NUAK2,
QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4 and
MELK) closely related to AMPKα1 and AMPKα2 have
been identified in the human kinome, thus forming a 14
kinase phylogenetic tree known as ‘AMPK-related
kinases’ [3, 4]. LKB1, an upstream activating kinase of
AMPK, phosphorylates and activates 11 of the AMPK-
related kinases [3]. Although the role of AMPK-related
kinases is largely unknown, they do not appear to interact
with the regulatory β and γ subunits of AMPK [5].
Furthermore, the majority of the AMPK-related kinases
are not activated by AMP or pharmacological activators of
AMPK including 5-aminoimidazole-4-carboxamide-1β-4-
ribofuranoside (AICAR) and phenformin [3, 6]. Recent
evidence suggests that skeletal muscle-selective knockout
of LKB1 increases insulin sensitivity [7], possibly impli-
cating these novel AMPK-related protein kinases in the
regulation of glucose homeostasis.
Haploinsufficient Snark (also known as Nuak2) knock-
out mice develop obesity, hepatic steatosis, altered serum
lipid profiles, hyperinsulinaemia, hyperglycaemia and im-
paired glucose tolerance with age [8]. SNARK was first
identified as an ultraviolet B-induced gene in keratinocytes
[9]. SNARK is located on human chromosome 1q32 and is
translated into a single protein of approximately 76 kDa
[10]. In rats, Snark is expressed in multiple tissues, with
highest expression in kidney [11]. Sucrose, non-fermenting
1/AMP-activated protein kinase-related kinase (SNARK) is
activated in a cell-type-specific manner by a variety of
stressors including hyperosmotic stress, DNA damage and
oxidative stress, as well as nutrients including glucose and
glutamine [10, 11]. Several aspects of SNARK activation
and regulation are broadly similar to AMPK [12]. For
example, SNARK and AMPK are both AMP-responsive
and activated by treatments known to increase the AMP:
ATP ratio, including glucose deprivation and chemical ATP
production [10, 11, 13]. Nevertheless, the metabolic role of
SNARK, particularly in humans and at the cellular level in
skeletal muscle, is incompletely resolved.
Given that Snark-haploinsufficient mice become obese
and glucose-intolerant [8], this AMPK-related protein
kinase may play a permissive role in energy metabolism.
Thus, we tested the hypothesis that SNARK is involved in
cellular stress responses associated with obesity and type 2
diabetes. Since skeletal muscle plays an important role in
the regulation of whole-body glucose uptake, the aim of
this study was to determine the role of SNARK in response
to metabolic stress and insulin action on glucose and lipid
metabolism in human skeletal muscle.
Methods
Study participants and muscle biopsy procedure Biopsies
were obtained using a Weil–Blakesley conchotome from
vastus lateralis skeletal muscle under local anaesthesia
(lidocaine hydrochloride 5 mg/ml) from normal glucose
tolerant and type 2 diabetic men and women for mRNA
expression analysis of the gene encoding SNARK. Biopsies
were snap-frozen and stored in liquid nitrogen until use. The
clinical characteristics of the study participants are presented
in Table 1. HOMA2-insulin resistance (IR) values were
determined using the HOMA calculator (www.dtu.ox.ac.uk).
Table 1 Participant characteristics
Sex Age (years) BMI
(kg/m
2)
Fasting glucose
(mmol/l)
HbA1c
(%)
Triacylglycerol
(mmol/l)
Insulin
(pmol/l)
HOMA2-IR
Normal glucose tolerant
BMI <28 kg/m
2 10 F/8 M 59±1 26.2±0.2 5.3±0.1 4.6±0.05 1.15±0.14 51.2±9.2 1.0±0.2
BMI >31 kg/m
2 11 F/6 M 61±1 34.4±0.9* 5.5±0.1 4.8±0.07* 1.49±0.14 59.7±7.1 1.1±0.1
Type 2 diabetic
BMI <28 kg/m
2 2 F/12 M 60±1 27.0±0.3* 7.8±0.4* 6.1±0.23* 1.34±0.13 53.0±6.5 1.1±0.1
BMI >31 kg/m
2 3 F/14 M 60±1 34.5±0.8* 7.8±0.4* 5.9±0.19* 1.53±0.10* 91.4±11.5* 1.9±0.21*
Data are means±SE
*p<0.05 compared with normal glucose tolerant individuals with BMI <28 kg/m
2
F, female; M, male
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consent was received from all study participants.
Skeletal muscle cell cultures and in vitro treatments Skeletal
muscle cell cultures were established from satellite cells
isolatedfromvastuslateralisskeletalmusclebiopsiesobtained
from normal glucose tolerant individuals. Satellite cells were
isolated by trypsin–EDTA digestion, and myoblasts were
cultured and differentiated into myotubes as previously
described [14]. Myotubes were used to test the effects of a
variety of cellular stressors, including nutrients, hormones or
cytokines, on SNARK mRNA expression. Myotubes were
treated with palmitate (0.25 mmol/l), oleate (0.25 mmol/l),
glucose (25 mmol/l), TNF-α (20 ng/ml) or IL-6 (20 ng/ml)
for 2 or 7 days. SNARK mRNA expression was determined
as described below.
To determine the direct role of SNARK on basal and
insulin-stimulated glucose and lipid metabolism, myoblasts
were transfected with small interfering (si) RNA against a
scrambled non-specific sequence or SNARK (80 pmol)
(Ambion/Applied Biosystems, Foster City, USA) for 16 h
before initiation of differentiation and also after 2 days into
the differentiation programme using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) in serum- and antibiotic-
free DMEM [15]. Glucose incorporation into glycogen and
lipid oxidation were determined, as described below.
SNARK mRNA expression SNARK mRNA expression was
assessed in vastus lateralis skeletal muscle biopsies or
primary skeletal muscle cell cultures (myotubes) using
quantitative RT-PCR (ABI PRISM 7000 Sequence Detector
System; Applied Biosystems). Total RNA was purified
from skeletal muscle biopsies using Trizol reagent (Invi-
trogen, Carlsbad, CA, USA) and from myotubes using an
RNeasy Mini Kit (Invitrogen). Purified RNAwas treated with
DNase I using a DNA-free kit (Ambion) and cDNA synthesis
was performed with a SuperScript First Strand Synthesis
System (Invitrogen). TaqMan gene expression assays
(Hs00388292_m1 and Hs00178903_m1) for SNARK and
AMPKα2 (also known as PRKAA2)m R N Ae x p r e s s i o nw e r e
independently used in multiplex, with β2-microglobulin as a
reference gene (Applied Biosystems). All samples where
assayed in duplicate. The mRNA relative abundance was
calculated using the standard curve method as described by
Applied Biosystems.
Glycogen synthesis in skeletal muscle cells Glucose incor-
poration into glycogen was determined as described [16].
Myotubes were incubated in the absence or presence of either
6 or 60 nmol/l insulin for 30 min and thereafter incubated for
90 min with D-[U-
14C]glucose (3700 Bq/ml; Amersham,
Uppsala, Sweden) in DMEM (1 g glucose/l). When indicated,
myotubes were exposed to either palmitate (0.25 mmol/l) or
TNF-α (20 ng/ml) for 48 h before the experiment was
performed. Experiments were performed in duplicate. Results
are reported as nmol glucose (mg protein)
−1 h
−1.
Lipid oxidation in skeletal muscle cells NEFA oxidation
was assessed by exposing myotubes to [
3H]palmitic acid
and measuring the production of
3H-labelled water. Myo-
tubes were cultured in six well plates and serum starved
overnight. Cells were washed once with PBS and incubated
for 5.5 h with 1 ml DMEM (1 g glucose/l), supplemented
with fatty acid-free BSA (0.2% wt/vol.) and [9,10(n)-
3H]
palmitic acid (1850 Bq/ml; Amersham), with or without
insulin (120 nmol/l) or AICAR (1 mmol/l; Toronto
Research Chemicals, Toronto, ON, Canada). To absorb
non-metabolised palmitate, 0.2 ml of the cell supernatant
was mixed with 0.8 ml charcoal slurry (0.1 g charcoal
powder in 1 ml 0.02 mol/l TRIS–HCl buffer, pH 7.5) in a
2 ml Eppendorf tube and shaken for 30 min. Samples were
subjected to centrifugation at 18,500×g for 15 min, after
which 0.3 ml supernatant with
3H-labelled-bound water
was withdrawn, and radioactivity was determined by liquid
scintillation counting (WinSpectral 1414 Liquid Scintilla-
tion Counter; Wallac, Turku, Finland). Each experiment
was performed in duplicate. Results are reported as per cent
converted palmitate (mg protein)
−1 h
−1.
Western blot analysis Lysates were prepared from myo-
tubes transfected with siRNA against a scrambled sequence
or SNARK. Proteins were separated by SDS-PAGE and
subjected to immunoblot analysis with an antibody directed
against SNARK (Proteintech, Manchester, UK). Proteins
where visualised by enhanced chemiluminescence and
quantified by densiometry. Results are reported as arbitrary
units and normalised to a loading control (desmin).
Statistics Results are presented as means±SE. Differences
between groups were determined by Student’s t test or two-
way ANOVA. When ANOVA was applied, pair-wise
multiple comparison procedures were performed using the
Holm–Sidak method at a significance level of 0.05.
Results
Skeletal muscle SNARK mRNA expression is increased with
obesity but not in diabetes SNARK mRNA expression was
determined in vastus lateralis skeletal muscle biopsies from
normal glucose tolerant and type 2 diabetic men and
women (Fig. 1). Type 2 diabetic patients had fasting
hyperglycaemia, and elevated HbA1c levels, compared with
normal glucose tolerant individuals (p<0.05). Individuals
2184 Diabetologia (2009) 52:2182–2189were stratified into two groups based on BMI. The
metabolic derangements were exacerbated in the obese
(BMI >31 kg/m
2) vs overweight (BMI <28 kg/m
2) type 2
diabetic patients, who also had increased HOMA2-IR
values (p<0.05). SNARK mRNA expression was increased
1.4-fold in obese normal glucose tolerant individuals (BMI
>31 kg/m
2) vs overweight normal glucose tolerant individ-
uals (BMI <28 kg/m
2). SNARK mRNA was also increased
1.4-fold in obese type 2 diabetic patients (BMI >31 kg/m
2)
vs overweight type 2 diabetic patients (BMI <28 kg/m
2).
SNARK mRNA expression was similar in normal glucose
tolerant and type 2 diabetic patients, irrespectively of BMI.
Effects of cellular stressors on SNARK mRNA expres-
sion SNARK mRNA expression was assessed in cultured
myotubes treated with a variety of nutrients or cytokines for
2 days (Fig. 2a). Exposure of myotubes to either palmitate
(12-fold; p<0.01) or TNF-α (25-fold, p<0.05), but not
oleate, glucose or IL-6, increased SNARK mRNA expres-
sion compared with untreated myotubes, whereas expres-
sion of the AMPKα2 subunit was unaltered (Fig. 2b).
Similar responses on SNARK mRNA expression were also
observed in myotubes exposed to these metabolic stressors
for 7 days (data not shown). Furthermore, SNARK mRNA
expression was unaltered following exposure of myotubes
to AMPK activators, including AICAR, metformin or
rosiglitazone (data not shown).
SNARK silencing in myotubes The effect of SNARK gene
silencing on mRNA expression (Fig. 3a) and protein level
(Fig. 3b) was determined in cultured myotubes. siRNA
against SNARK reduced mRNA expression by 61% and
protein content by 60% compared with myotubes trans-
fected with siRNA against a scrambled sequence.
Role of SNARK on glucose incorporation into glycogen Glu-
cose incorporation into glycogen was assessed in myotubes
transfected with siRNA against a scrambled sequence or
SNARK (Fig. 4). Insulin increased glucose incorporation
into glycogen in myotubes transfected with siRNA against
a scrambled sequence (1.8- and 2.3-fold in the presence of
6 or 60 nmol/l insulin, respectively; p<0.05 vs basal).
Similar effects of insulin on glucose incorporation into
glycogen were noted for myotubes transfected with siRNA
against SNARK (1.8- and 2.4-fold increase in the presence
of 6 or 60 nmol/l insulin, respectively; p<0.05 vs basal).
SNARK silencing did not influence basal and insulin-
stimulated glucose incorporation into glycogen.
Role of SNARK on lipid oxidation Lipid oxidation was
determined in myotubes transfected with siRNA against a
scrambled sequence or SNARK (Fig. 5). Insulin suppressed
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Fig. 2 Effect of cellular stressors on SNARK mRNA expression.
Cultured myoblasts were treated with palmitate (0.25 mmol/l), oleate
(0.25 mmol/l), glucose (25 mmol/l), TNF-α (20 ng/ml) or IL-6 (20 ng/
ml) for 2 days followed by assessment of SNARK mRNA expression
(a) and AMPKα2 mRNA expression (b). Results are reported in
arbitrary units (A.U.) as means±SE for n=5 individual cultures.
*p<0.05 compared with unstimulated control cells
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Fig. 1 SNARK mRNA expression was determined in vastus lateralis
skeletal muscle biopsies from normal glucose tolerant individuals and
type 2 diabetic patients with BMI <28 kg/m
2 (white bars) and BMI
>31 kg/m
2 (black bars). Result are reported in arbitrary units (A.U.) as
means±SE for n=14–18 individuals. *p<0.05 compared with normal
glucose tolerant individuals with BMI <28 kg/m
2
Diabetologia (2009) 52:2182–2189 2185lipid oxidation in myotubes transfected with siRNA against
a scrambled sequence (14%; p<0.05) and this effect was
unaltered by SNARK silencing. AICAR increased lipid
oxidation in myotubes transfected with siRNA against
either a scrambled sequence (3.5-fold; p<0.01) or SNARK
(3.2-fold; p<0.01) vs the basal condition. Thus, SNARK
silencing did not influence basal or insulin- or AICAR-
stimulated lipid oxidation.
Effect of SNARK silencing on TNF-α- or palmitate-induced
insulin resistance Given that TNF-α and palmitate treat-
ment markedly increased SNARK mRNA expression, we
also examined whether protein levels were altered under
these conditions (Fig. 6a). Exposure of myotubes to either
TNF-α or palmitate for 48 h increased SNARK protein
content (p<0.05). SNARK silencing reduced protein content
by 56% (p<0.05), and completely prevented the effect of
either TNF-α or palmitate to increase SNARK protein.
Exposure of myotubes to TNF-α or palmitate induces
insulin resistance in cultured human myotubes [17, 18],
coincident with increased SNARK expression (Fig. 2a).
Thus, we determined whether SNARK silencing prevents
insulin resistance arising from these factors (Fig. 6b).
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Fig. 5 Role of SNARK in lipid oxidation. Lipid oxidation was
measured in myotubes transfected with siRNA against either a
scrambled sequence (Scr) or SNARK and incubated in the absence
(basal; white bars) or presence of either insulin (60 nmol/l; grey bars)
or AICAR (1 mmol/l; black bars). Results are means±SE for n=
8 individual cultures. *p<0.05 compared with basal scrambled
siRNA-transfected myotubes
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Fig. 4 Role of SNARK in glucose incorporation into glycogen. Glucose
incorporation into glycogen was measured in myotubes transfected with
either siRNA against a scrambled sequence (Scr) or SNARK and
incubated in the absence (basal; white bars) or presence of a submaximal
(6 nmol/l; grey bars) or maximal (60 nmol/l; black bars) concentration of
insulin. Results are means±SE for n=8 individual cultures. *p<0.05
compared with basal scrambled siRNA-transfected myotubes
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Fig. 3 SNARK gene silencing in primary human myotubes. The effect
of SNARK siRNA was determined on mRNA expression (a) and
protein levels (b). Results are reported in arbitrary units (A.U.) as
means±SE for n=4 individual cultures. *p<0.05 compared with
myotubes treated with siRNA against a scrambled (Scr) sequence. IB,
immunoblot
2186 Diabetologia (2009) 52:2182–2189Myotubes were transfected with siRNA against either a
scrambled sequence or SNARK and incubated for 48 h in
the absence or presence of TNF-α (20 ng/ml) or palmitate
(0.25 mmol/l). TNF-α exposure decreased insulin-
stimulated glucose incorporation into glycogen by 41% in
the presence of 6 nmol/l (p<0.05), but not 60 nmol/l insulin,
in myotubes treated with siRNA against either a scrambled
sequence or SNARK. Thus, siRNA against SNARK does not
protect against TNF-α-induced insulin resistance. Palmitate
exposure decreased insulin-stimulated glucose incorpora-
tion into glycogen by 37% in the presence of 60 nmol/
l insulin (p<0.01), but not 6 nmol/l insulin, in myotubes
treated with siRNA against either a scrambled sequence or
SNARK. Thus, siRNA against SNARK does not protect
against palmitate-induced insulin resistance.
Discussion
The AMPK-related kinase SNARK plays a role in whole-
body glucose and energy homeostasis [8]. Whole-body
Snark-haploinsufficient mice are obese and glucose-
intolerant, implicating an important role for this AMPK-
related protein kinase in the regulation of energy and
glucose homeostasis [8]. Here we tested the hypothesis that
SNARK is involved in cellular stress responses linked to
the development of insulin resistance in obesity and type 2
diabetes. We provide evidence that SNARK mRNA expres-
sion is increased in skeletal muscle from obese normal
glucose tolerant and type 2 diabetic men and women. The
increase in SNARK mRNA was unaltered between normal
glucose tolerant and type 2 diabetic individuals irrespec-
tively of BMI, indicating the influence of obesity, rather
than diabetes per se. Based on the phenotype of the Snark-
haploinsufficient mice [8], an increase in SNARK mRNA
expression would be predicted to have a positive effect on
energy and glucose homeostasis, but this does not appear
to be the case, at least in humans. We also report that
elevated levels of TNF-α or palmitate, systemic factors
implicated in obesity-induced insulin resistance, increased
SNARK expression in cultured human skeletal muscle
myotubes. Nevertheless, a 60% reduction in SNARK
mRNA by siRNA-mediated gene silencing (an effect
similar to that achieved in whole-body Snark-haploinsuf-
ficient mice [8]), was without effect on basal or insulin-
stimulated glucose uptake and lipid oxidation. Furthermore,
SNARK silencing did not prevent TNF-α-o rp a l m i t a t e -
induced insulin resistance in skeletal muscle. Thus, while
obesity and associated systemic factors, such as TNF-α or
palmitate increase SNARK mRNA expression, insulin resis-
tance induced by these factors occurs via a SNARK-
independent mechanism.
Snark-haploinsufficient mice, with a 50% reduction of
whole-body Snark mRNA expression, develop obesity and
insulin resistance, as evidenced by increased adiposity, fatty
liver, increased serum triacylglycerol, hyperinsulinaemia,
hyperglycaemia and glucose intolerance [8]. Thus, our
findings of increased skeletal muscle SNARK mRNA
expression in obese humans and in response to elevated
levels of TNF-α or palmitate in vitro, suggest that the
metabolic phenotype observed in total-body Snark-haploin-
sufficient mice is unlikely to arise from a direct effect of
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Fig. 6 Effect of SNARK silencing on TNF-α- and palmitate-induced
insulin resistance. Human myotubes were transfected with either siRNA
against a scrambled sequence (Scr) or SNARK and incubated in the
absence (basal; white bars) or presence of TNF-α (20 ng/ml; grey bars)
or palmitate (0.25 nmol/l; black bars) for 48 h and the effect of SNARK
siRNA silencing was determined on protein levels (a). Glucose
incorporation into glycogen was measured in the absence or presence
of insulin (b) in myotubes transfected with siRNA against Scr (white
bars) or SNARK (black bars). Results are means±SE for n=4 individual
cultures. *p<0.05 compared with myotubes incubated in the absence of
insulin. †p<0.05 compared with myotubes incubated in the absence of
TNF-α and palmitate (basal). A.U. arbitrary units; IB, immunoblot
Diabetologia (2009) 52:2182–2189 2187SNARK in skeletal muscle. Rather, these results implicate a
role for SNARK in other tissues, particularly since skeletal
muscle expresses relatively low levels of SNARK com-
pared with liver, kidney, intestine and testis in rodents [11].
The development of mature-onset obesity in whole-body
Snark-heterozygous mice might occur from a central defect
that modifies food intake and activity levels, rather than a
direct effect in peripheral tissues. The absence of a basal
energetic defect in skeletal muscle of Snark-heterozygous
mice, as well as an unexplained increased motivation/drive
for voluntary exercise supports this contention [19]. Fibre
type composition and number is unaffected in Snark-
heterozygous mice, indicating Snark expression and
activity in tissues other than skeletal muscle may contrib-
ute to the regulation of glucose and energy homeostasis and
motivation for physical activity. For example, impairments in
brownadiposetissuemaycontributetotheobesityphenotype,
since whole-body temperature and energy expenditure was
reduced in these mice. Further studies using tissue-specific
Snark knockout mice may resolve this paradox.
The identification of an AMPK subfamily [3] raises
questions about the involvement of these protein kinases in
whole-body and cellular glucose and energy homeostasis,
as well as the possibility that they might regulate cellular
and whole-body metabolic and gene regulatory responses in
a manner analogous to AMPK. Lkb1 (also known as Stk11)
knockout mice have been important in the evaluation of the
metabolic role of the AMPK-related kinases, since it is a
master kinase that activates the majority of the members of
this subfamily [3]. For example, contraction-mediated
glucose uptake is inhibited in skeletal muscle from Lkb1
knockout mice [20] and kinase-dead Ampkα2 transgenic
mice [21], but not Ampkα1 and Ampkα2 isoform-specific
knockout mice [22], indicating both AMPK-dependent and
AMPK-independent pathways may play a role. Moreover,
skeletal muscle-selective knockout of Lkb1 increases
whole-body and skeletal muscle insulin sensitivity and
improves glucose homeostasis [7], implicating AMPK-
related protein kinases participate in the negative regulation
of insulin action. Given our observation that SNARK
mRNA expression was elevated in skeletal muscle from
obese humans and myotubes exposed to TNF-α or
palmitate, we tested the hypothesis that SNARK silencing
would directly alter insulin action on glucose and lipid
metabolism. However, neither basal nor insulin-stimulated
glucose incorporation into glycogen was altered by SNARK
silencing in primary human myotubes. Furthermore, basal,
as well as insulin- or AICAR-stimulated beta oxidation was
unchanged by SNARK silencing. This contrasts with earlier
findings which revealed that AMPKα subunit silencing
prevents the effects of IL-6 to promote beta oxidation into
human myotubes [23]. Thus, AMPK, rather than SNARK,
appears to control lipid oxidation in skeletal muscle.
Although siRNA against SNARK reduced mRNA expres-
sion by 60%, we cannot exclude the possibility that a total
knockout of SNARK may be required to reveal effects on
glucose and lipid metabolism.
OurobservationofincreasedSNARK mRNA expression in
skeletal muscle from obese humans, and in response to TNF-
α or palmitate treatment, potentially connects SNARK to
metabolic regulation in response to cellular stress signals.
For example, TNF-α secretion from adipose tissue is
increased and IL-6 serum levels are elevated in obese
insulin-resistant individuals [24]. Thus, the intracellular
communication between adipocytes or macrophages in
obesity may provide stress signals that increase SNARK
expression in skeletal muscle, which may modify insulin
action. Nevertheless, siRNA against SNARK failed to prevent
the development of TNF-α- or palmitate-induced insulin
resistance on glucose incorporation into glycogen. Previous
studies from our laboratory provide evidence that siRNA-
mediated reduction of either the mitogen-activated protein
kinase kinase kinase kinase isoform 4 [15] or the inhibitor of
nuclear factor-kappaβ (NF-κβ)k i n a s e[ 17]p r e v e n t sT N F - α-
induced insulin resistance in human skeletal muscle. Inter-
estingly, SNARK has anti-apoptotic properties, acting
through a TNF-α-sensitive nuclear NF-κβ-mediated mech-
anism [25]. Thus, the increase in SNARK expression may be
a consequence, rather than a cause of skeletal muscle insulin
resistance.
In conclusion, we provide evidence against a role for
SNARK in the regulation of skeletal muscle glucose or
lipid metabolism. Nevertheless, obesity, but not type 2
diabetes, is associated with an increase in skeletal muscle
SNARK mRNA expression in humans. This increase in
SNARK mRNA expression may occur as a consequence of
systemic factors associated with metabolic impairments in
obesity, since exposure of myotubes to elevated levels of
TNF-α or palmitate acutely increased SNARK mRNA
expression. siRNA against SNARK failed to rescue TNF-
α- or palmitate-induced insulin resistance, indicating
changes in SNARK expression occur as a consequence,
rather than a cause of insulin resistance. Based on our
findings in human skeletal muscle, and the insulin-resistant
and obesity phenotype in whole-body Snark-haploinsuffi-
cient mice [8], SNARK expression in metabolically active
tissues beyond skeletal muscle may play a role in whole-
body energy and glucose homeostasis.
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